Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
25 de febrero de 2016 actualizado por: Hoffmann-La Roche
Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples.
No patients will be enrolled in this study.
Data will be collected for approximately 6 months.
Descripción general del estudio
Estado
Terminado
Condiciones
Tipo de estudio
De observación
Inscripción (Actual)
420
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Boulogne Billancourt, Francia, 92104
-
Colmar, Francia, 68024
-
Lille, Francia, 59037
-
Lyon, Francia, 69437
-
Marseille, Francia, 13015
-
Montpellier, Francia, 34295
-
Nantes, Francia, 44093
-
Paris, Francia, 75010
-
Pessac, Francia, 33604
-
Rouen, Francia, 76031
-
Vandoeuvre Les Nancy, Francia, 54511
-
Villejuif, Francia, 94505
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra de probabilidad
Población de estudio
No patients are enrolled in this study.
Use of melanoma tumor samples.
Descripción
Inclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Histologically proven melanoma tumor sample
- Any type of tumor sample: biopsy or surgical specimen of primary tumor or metastasis
- Tumor samples must be fixed and paraffin-embedded.
Exclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Fixative unknown
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
INCa molecular genetics laboratory "in-house" methods
BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods
|
|
Cobas 4800 Mutation Test
BRAF V600 mutations were analysed using Cobas 4800 mutation test
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories
Periodo de tiempo: Up to 6 months
|
BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test.
Samples were analysed as V600 mutation, No V600 mutation and Non evaluable.
Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method.
|
Up to 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Tumor Sample Characteristics-Type of Tumor Sample
Periodo de tiempo: Up to 6 months
|
The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported
|
Up to 6 months
|
|
Tumor Sample Characteristics - Source of Tumor Sample
Periodo de tiempo: Up to 6 months
|
The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported
|
Up to 6 months
|
|
Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated.
|
Up to 6 months
|
|
Time From Sampling to Fixation- Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown.
Number of samples falling in each of the class were reported.
|
Up to 6 months
|
|
Type of Fixative Used- Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported.
|
Up to 6 months
|
|
Fixation Duration by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
Fixation duration is defined as the amount of time required in hours for the fixation of a samples.
The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown.
Number of samples falling in each category were reported
|
Up to 6 months
|
|
Slice Thickness by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
Slice thickness of all the tumour samples was measured.
The slice thickness was measured in micrometer.
|
Up to 6 months
|
|
Dewaxing by Pre-analytical Method
Periodo de tiempo: Up to 6 Months
|
Dewaxing is a method to recover the DNA from samples.
Dewaxing information was collected as "Yes, No or Missing"
|
Up to 6 Months
|
|
Necrosis Percentage Determination by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported.
|
Up to 6 months
|
|
Percentage of Tumor Cells by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The percentage of tumor cells in the given tumor sample were reported.
|
Up to 6 months
|
|
Tumor Samples With Presence of Melanin by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent.
|
Up to 6 months
|
|
DNA Extraction - Extraction Method by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
This method assessed DNA from the tumor samples was extracted by Automated method or Manual method.
|
Up to 6 months
|
|
Median DNA Elution Volume by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
Median DNA elution volume microliters [mcl] was reported.
|
Up to 6 months
|
|
Mean DNA Concentration by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL).
|
Up to 6 months
|
|
Amount of DNA by Pre-analytical Method
Periodo de tiempo: Up to 6 months
|
The total DNA concentration extracted from the tissue was measured in nanogram (ng).
|
Up to 6 months
|
|
Size of Amplicons Used by "In-house" Analytical Method
Periodo de tiempo: Up to 6 months
|
The method described the size of amplicon used.
It was measured in base pairs (bp).
|
Up to 6 months
|
|
Method of Mutation Detection by "In-house" Analytical Method
Periodo de tiempo: Up to 6 months
|
Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection.
|
Up to 6 months
|
|
Number of Samples Punched in In-house Analytical Method
Periodo de tiempo: Up to 6 months
|
Total number of samples for whom punch was used in 'in-house analytical' method are reported.
|
Up to 6 months
|
|
Mean Number of Slices Per Sample Used for "In-house"- Analytical Method
Periodo de tiempo: Up to 6 months
|
The mean of number of slices per sample when no punch was used are reported.
|
Up to 6 months
|
|
Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method
Periodo de tiempo: Up to 6 months
|
This In-house analytical method measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method
Periodo de tiempo: Up to 6 months
|
The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours.
|
Up to 6 months
|
|
Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method
Periodo de tiempo: Up to 6 months
|
The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported.
The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl)
|
Up to 6 months
|
|
Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Periodo de tiempo: Up to 6 months
|
The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No.
|
Up to 6 months
|
|
Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Periodo de tiempo: Up to 6 months
|
This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used.
Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples.
|
Up to 6 months
|
|
Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method
Periodo de tiempo: Up to 6 months
|
This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method
Periodo de tiempo: Up to 6 months
|
This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results.
The time duration was measured in hours.
|
Up to 6 months
|
|
Management of Discordance- Method Used to Manage Discordance
Periodo de tiempo: Up to 6 months
|
Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm.
tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test.
|
Up to 6 months
|
|
Management of Discordance-Final Result for BRAF V600 Mutation Detection
Periodo de tiempo: Up to 6 months
|
The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable.
These results were further assessed by the Investigator and interpreted as final result.
|
Up to 6 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de diciembre de 2012
Finalización primaria (Actual)
1 de abril de 2013
Finalización del estudio (Actual)
1 de abril de 2013
Fechas de registro del estudio
Enviado por primera vez
6 de diciembre de 2012
Primero enviado que cumplió con los criterios de control de calidad
6 de diciembre de 2012
Publicado por primera vez (Estimar)
7 de diciembre de 2012
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
28 de marzo de 2016
Última actualización enviada que cumplió con los criterios de control de calidad
25 de febrero de 2016
Última verificación
1 de noviembre de 2015
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ML28471
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .